We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    ((BAY86-9766 AND GIST) OR NCT01392521)
Previous Study | Return to List | Next Study

Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01392521
Recruitment Status : Completed
First Posted : July 12, 2011
Last Update Posted : April 17, 2015
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:

The PI3K (phosphoinositol 3-Kinase) inhibitor Copanlisib and the MEK (mitogen-activated protein kinase) inhibitor Refametinib (BAY86-9766)have both been tested as single agent treatments in other phase I studies. This study will test the combination of these two drugs to try and answer the following questions:

  1. What are the side effects of the combination of Copanlisib and Refametinib (BAY86-9766)when given together at different/increasing dose levels?
  2. What dose level of Copanlisib and Refametinib (BAY86-9766) should be tested in future clinical research studies?
  3. How much Copanlisib is in the blood at specific times after administration and does adding Refametinib (BAY86-9766) have an affect?
  4. How much Refametinib (BAY86-9766) is in the blood at specific times after administration and does adding Copanlisib have an affect?
  5. Does the combination of Refametinib (BAY86-9766) and Copanlisib have an effect on tumors?

Condition or disease Intervention/treatment Phase
Neoplasms Drug: Copanlisib + Refametinib (BAY86-9766) Phase 1

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib Trial of the Combination of PI3K Inhibitor BAY 80-6946 and Allosteric-MEK Inhibitor BAY 86-9766 in Subjects With Advanced Cancer
Study Start Date : July 2011
Primary Completion Date : February 2014
Study Completion Date : April 2014
Arms and Interventions

Arm Intervention/treatment
Experimental: Arm 1 Drug: Copanlisib + Refametinib (BAY86-9766)
Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
Drug: Copanlisib + Refametinib (BAY86-9766)
Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.


Outcome Measures

Primary Outcome Measures :
  1. Maximum Tolerated Dose [ Time Frame: 2 years ]
  2. Comparison of the Copanlisib AUC when given alone with the AUC when given with Refametinib (BAY86-9766) [ Time Frame: At day 15 ]
  3. Comparison of the Refametinib (BAY86-9766) AUC when given alone with the AUC when given with Copanlisib [ Time Frame: At day 15 ]

Secondary Outcome Measures :
  1. Tumor Response as measured by RECIST 1.1 criteria [ Time Frame: 3 years ]
  2. Biomarker evaluation including analysis of pathway activation in blood and plasma [ Time Frame: 3 years ]
  3. Tumor Response as measured by FDG-PET at MTD and expansion cohort(s) [ Time Frame: 3 years ]
  4. Pharmacodynamic biomarker evaluation analysis using paired tumor biopsies [ Time Frame: 3 years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age greater than/equal to 18 years old
  • ECOG Performance Status of 0 - 1
  • Life expectancy of at least 12 weeks
  • Patients with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy or have no standard therapy available
  • LVEF (left ventricular ejection fraction) > or = to the lower limit of normal for the institution
  • Radiographically or clinically evaluable tumor
  • Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to start of first dose:

    • Hemoglobin > 9.0 g/dL
    • Absolute neutrophil count (ANC) > or = 1500/mm3
    • Platelet count > or = 100,000 /mm3
    • Total bilirubin < or = 1.5 times the upper limit of normal
    • ALT (alanine aminotransferase) and AST (aspartate aminotransferase) < or = 2.5 x upper limit of normal (< or = 5 x upper limit of normal for patients with liver involvement)
    • PT-INR (prothrombin-international normalized ratio) and PTT (partial thromboplastin time) < or = 1.5 times the upper limit of normal
    • Serum creatinine < or = 1.5 times the upper limit of normal

Exclusion Criteria:

  • History of impaired cardiac function or clinically significant cardiac disease (i.e. congestive heart failure (CHF) NYHA (New York Heart Association) Class III or IV); active coronary artery disease, myocardial infarction within 6 months of study entry; new onset or unstable angina within 3 months of study entry, or cardiac arrhythmias requiring anti-arrhythmic therapy
  • Type 1 or type 2 diabetes mellitus or fasting glucose > 125 mg/dL or HgBA1c > or = 7.0
  • Use of systemic corticosteroids within 2 weeks of study entry
  • History of retinal vein occlusion
  • Known glucose-6-phosphate dehydrogenase (G6PD) deficiency
  • Active clinically serious infection
  • Uncontrolled hypertension
  • Positive for HIV, or chronic Hepatitis B or C
  • Subjects undergoing renal dialysis
  • Known bleeding diathesis
  • Ongoing substance abuse
  • Pregnant or breast-feeding women
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01392521


Locations
United States, Arizona
Scottsdale, Arizona, United States, 85260
United States, Nevada
Las Vegas, Nevada, United States, 89169
United States, South Carolina
Greenville, South Carolina, United States, 29605
United States, Texas
Houston, Texas, United States, 77030
Tyler, Texas, United States, 75702
United States, Washington
Vancouver, Washington, United States, 98684
Germany
Freiburg, Baden-Württemberg, Germany, 79106
Netherlands
Rotterdam, Netherlands, 3015 CE
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01392521     History of Changes
Other Study ID Numbers: 12876
2010-024082-45 ( EudraCT Number )
First Posted: July 12, 2011    Key Record Dates
Last Update Posted: April 17, 2015
Last Verified: April 2015

Keywords provided by Bayer:
Safety
Tolerability
Pharmacokinetics